Evasc is a medical device company focused on novel solutions for the endovascular repair of cerebral aneurysms, to provide a much higher standard of care and rate of successful treatment outcomes than previously possible.
Evasc’s lead device, the eCLIPs Aneurysm Remodeling System, has been in development since 2008 and is protected by multiple patents. eCLIPs is designed to treat 95% of cerebral aneurysms, including challenging wide-neck bifurcations. The first use of eCLIPs in a human patient was performed in 2013 under Health Canada’s Special Access Program. eCLIPs received EU Mark approval in 2014, FDA HUD designation in December 2015, and is part of an ongoing clinical trial in Europe known as the European eCLIPs Safety, Feasibility and Efficacy Study (EESIS).